LLY
Eli Lilly and Company
LLY (Eli Lilly and Company) has a reliability-weighted signal score of 59/100 on StockMarketSignals, based on 4 finance YouTubers over a rolling 14-day window. The score reflects how strongly tracked creators are currently bullish or bearish on LLY, weighted by each channel's reliability.
Why analysts are watching it
Eli Lilly is drawing analyst attention due to a mix of strong drug performance and competitive market dynamics. On May 24, 2026, Couch Investor highlighted that Eli Lilly's drug Monjurro became the best-selling drug in Q1 2026, generating $8.7 billion. Adding to this positive sentiment, Couch Investor expressed on July 7, 2026, that Eli Lilly should be up, not down. However, on June 16, 2026, The Patient Investor noted that while Novo Nordisk has been losing significant market share to Eli Lilly in obesity care, he also cautioned that the Lilly pill's performance might decline as people get used to competitor pills and more negative reviews emerge. The stock's perceived value was further discussed by Everything Money on July 2, 2026, who noted that the CEO of Eli Lilly, an Adobe board member, recently purchased nearly $2 million of the stock, while Asymmetric Investing by Travis Hoium noted on July 1, 2026, the presence of Eli Lilly's products on platforms like Hims & Hers. Investors should be aware that competition in the pharmaceutical space is intense and can quickly shift market share.
Contributing creators
Source clips
"Eli Lilly should maybe not be down 1.1%. I think it should be up 1.1%."
— The Most Mispriced Stocks Nobody Is Talking About Right Now
"And here's a big tell. An Adobe board member, the CEO of Eli Liy, just bought nearly $2 million of stock with his own personal money."
— I'm Buying 7 Stocks at Unthinkable Prices over the MAG 7 Right Now
"You've seen Eli Lilly's products now on Hims and Hers."
— Hims & Hers Stock: Why This Is a 10x Stock
"Now, to be fair, NVO has been losing massive market share to Lilly in obesity care."
— Novo Nordisk Stock Is Nearing An Inflection Point!
"Once people start taking those pills, they're going to get used to them and they see more reviews against the Lilly pill. So, the Lilly pill isn't going to do as well. This is exactly what happened."
— Novo Nordisk Stock Is Nearing An Inflection Point!
"Then we have here Eli Liy and Merk's cancer drug. Here you can see that last quarter in Q1 2026, Monurro from Eli Liy became the bestselling drug, $8.7 billion."
— I'm Thinking About Buying Next Week. Here's My Full Plan
Frequently asked about LLY
Is LLY a buy according to finance YouTubers?
Tracked finance YouTubers are currently mildly bullish / mixed on LLY (Eli Lilly and Company), giving it a reliability-weighted signal score of 59/100 on StockMarketSignals. This reflects creator sentiment over a rolling 14-day window and is not investment advice.
What is LLY's reliability score?
LLY has a StockMarketSignals reliability score of 59/100, based on 4 finance YouTubers. Scores above 60 indicate net-bullish creator sentiment, while scores below 40 indicate net-bearish sentiment.
Which finance YouTubers cover LLY?
LLY has been covered by Couch Investor, Asymmetric Investing by Travis Hoium, The Patient Investor, Everything Money on StockMarketSignals. Each creator is weighted by a reliability score based on the historical accuracy of their past calls.
How is the LLY signal calculated?
The LLY signal aggregates every tracked YouTuber mention, weighting each by the creator's reliability and decaying older mentions over a 90-day window. Bullish mentions push the score above 50, bearish mentions below it.